DT&CRO (PDG Chaekyu Park) a annoncé le August 22, 2025 that it a signé a strategic Protocole d'accord (MOU) with RudaCure (PDG Yongho Kim), a entreprise biotechnologienologique specializing in novel drug R&D.
This accord vise à respond to the increasingly sophisticated demand for développement de médicaments in the national and international pharmaceutique and bio industries, combining the expertise and strengths of both companies to achieve innovant R&D outcomes and global compétitivité.
The importance of strategic collaboration to enhance the efficiency of préclinique and essais cliniques and accelerate développement de médicaments is growing, and this accord was planned within this industrie trend.
Grâce à cela accord, both companies will closely collaborate in divers areas notamment: ▲discovery and R&D cooperation for candidat-médicament innovants, ▲préclinique and essai clinique planning and execution cooperation, and ▲establishment of data-based analysis and research support systems.
DT&CRO, as a specialized CRO (Contract Research Organization), possesses accumulated experience in préclinique and essai clinique planning and execution, ainsi que regulatory response capabilities. RudaCure's développement de médicaments innovants pipeline (notamment traitement de la sécheresse oculaire RCI001 and traitement de la douleur RCI002) and plateforme technology can achieve synergy effects when combined with DT&CRO's développement clinique infrastructure and operational expertise.
CEO Park of DT&CRO a déclaré : "This MOU with RudaCure devrait create significatif synergies in the préclinique and essai clinique fields. Through combining both companies' technologies and know-how, we will contribute to the national bio-pharmaceutique industrie's leap to the next level."
le PDG Kim of RudaCure a déclaré : "Through collaboration with DT&CRO's professional CRO experience and capabilities, we expect to more effectively advance the development of our new drugs notamment RCI001 and RCI002. We will work together to achieve tangible research outcomes."
